Kolon TissueGene, Inc. announced a private placement that it will issue Series 2 Non-Couponed, Non-Guaranteed Private Placement Convertible Bonds for the gross proceeds of KRW 24,500,000,000 on June 27, 2024. The transaction will include participation from Eugene Investment & Securities Co.,Ltd. for 9,000,000,000 shares; Hanyang Securities Co. Ltd. for 3,000,000,000 shares; Mirae Asset Securities Co., Ltd. for 2,000,000,000 shares; KB Securities Co.,Ltd for 1,000,000,000 shares; NH Investment & Securities Co., Ltd. for 1,500,000,000 shares; Korea Investment & Securities Co., Ltd. for 1,000,000,000 shares; Shinhan Investment & Securities Co., Ltd. for 2,000,000,000 shares and DB Financial Investment Co., Ltd. for 1,000,000,000 shares.

The bonds will be 100% convertible into 343,684 common shares at a conversion price of KRW 71,285 per share in a conversion period starting from July 5, 2025 and ending on June 5, 2029. The bonds will mature on July 5, 2029. The transaction is expected to close on July 5, 2024.

The transaction has been approved by the board of directors of the company.